Displaying drugs 11251 - 11275 of 11811 in total
FCX-013
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
Matched Description: … FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing …
BJ-001
BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding motif.
Investigational
Matched Description: … BJ-001 is a recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin-binding …
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
Matched Description: … MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of …
Zigakibart
Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With Iga Nephropathy).
Investigational
Matched Description: … Zigakibart is under investigation in clinical trial NCT05852938 (A Study of BION-1301 in Adults With …
BMS-564929
BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.
Experimental
Matched Description: … BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator …
Indium In-111 imciromab pentetate
Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium-111 which was used for cardiac imaging under the trade name Myoscint, but was withdrawn in 1993.
Withdrawn
Matched Description: … Indium In-111 imciromab pentetate is a mouse monoclonal antibody labelled with the radioisotope Indium …
TBX-3400
TBX-3400 is an investigational cell-based immunotherapy consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a recombinant TAT-MYC fusion protein.[L44281,L44286]
Investigational
Matched Description: … consisting of autologous peripheral blood mononuclear cells (PBMCs) treated ex vivo with TBX-4000, which is a …
NPI 32101
NPI 32101 possesses both anti-inflammatory and broad spectrum antimicrobial activities. This combination of pharmacological properties may have additional therapeutic uses beyond dermatology.
Investigational
Sphingosine
An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Experimental
Matched Description: … An amino alcohol with a long unsaturated hydrocarbon chain. …
Istiratumab
Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Investigational
Matched Description: … Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel …
SAR421869
SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
Investigational
Matched Description: … SAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the …
Horse chestnut
Horse chestnut is a flowering plant commonly referred to as Aesculus hippocastanum. Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases the risk of bleeding due to anticoagulant actions. These seeds are processed to remove the toxic component, resulting in purified horse chestnut seed extract...
Experimental
Matched Description: … Horse chestnut is a flowering plant commonly referred to as *Aesculus hippocastanum*. ... Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin) that increases …
Recifercept
Investigational
Ifenprodil
N-methyl-D-aspartate (NMDA) receptors (NMDARs) are members of the ionotropic glutamate receptor family, with key roles in brain development and neurological function.[A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding...
Investigational
Withdrawn
Matched Description: … domain (LBD), a transmembrane domain, and a C-terminal cytoplasmic domain. ... [A220118, A220128] NMDARs are heterotetramers that typically involve a dimer of dimers of both GluN1 ... and GluN2A-D subunits, with each subunit itself composed of an N-terminal domain (NTD), a ligand-binding …
Ciliary neurotrophic factor
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
Investigational
Edotreotide yttrium Y-90
Investigational
RP01
RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to millions of asthma and allergy patients.
Investigational
Matched Description: … RP01 is a novel anti-IgE immunotherapy for allergic individuals. …
Rhamnose
A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Experimental
Matched Description: … A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial …
V24343
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
Matched Description: … The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's …
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
Matched Description: … MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving …
Denibulin
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment …
NS-398
NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.
Experimental
Matched Description: … NS-398 is a COX-2 inhibitor. …
PF-5190457
PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).
Investigational
Matched Description: … PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations …
Pexastimogene devacirepvec
Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).
Investigational
Matched Description: … Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant …
JBPOS0101
JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Investigational
Matched Description: … JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 …
Displaying drugs 11251 - 11275 of 11811 in total